Given the observed heterogeneity in PLX4720 responses without an obvious biological mutational trend (Fig. 1A and Supplemental Table 1) and the variable metabolic strategies employed by our panel of BRAF-mutated melanomas, we sought to examine more closely whether a direct relationship exists between metabolism and drug response. The gene discussed is BRAF; the disease is melanoma.